• By Megan Forliti

Researchers reduce inflammation in human cells, A major cause of frailty

November 2, 2015

ROCHESTER, Minn. — Chronic inflammation, closely associated with frailty and age-related diseases, is a hallmark of aging. Mayo Clinic researchers have discovered that inhibiting key enzyme pathways reduces inflammation in human cells in culture dishes and decreases inflammation and frailty in aged mice.

two senior citizens, elderly couple walking down a road or path The results appear today in Proceedings of the National Academy of Sciences of the United States of America. While further studies are needed, researchers are hopeful that these findings will be a step toward treatments for frailty and other age-related chronic conditions.

In the study, researchers found that Janus kinase (JAK) inhibitors, drugs that work to block activity of JAK enzymes, decreased the factors released by human senescent cells in culture dishes. Senescent cells are cells that contribute to frailty and diseases associated with aging. Also, these same JAK inhibitors reduced inflammatory mediators in mice. Researchers examined aged mice, equivalent to 90-year-old people, before and after JAK inhibitors. Over the course of two months, the researchers found substantial improvement in the physical function of the aged mice, including grip strength, endurance and physical activity.

MEDIA CONTACT: Megan Forliti, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu 

Journalists: Sound bites with Dr. Kirkland are available in the downloads.

“One of the things we want to do is find some kind of treatment for this other than prescribing better wheelchairs or walkers, or other kinds of things that we are stuck with now that are Band-Aid solutions,” says James Kirkland, M.D., Ph.D., director of the Mayo Clinic Robert and Arlene Kogod Center on Aging and senior author of the study. A clinical geriatrician, Dr. Kirkland says he sees frailty in many of his elderly patients and that it’s often associated with poor outcomes and functional disability.

“Our goal is not necessarily to increase life span, and certainly not life span at all costs. Our goal is to enhance health span — the period during life when people are independent,” explains Dr. Kirkland. “This drug approach and others we are developing look like they might hold some promise in reaching that goal.”

The research was supported by National Institutes of Health grants AG041122 and AG013925 and a Glenn/American Federation for Aging Research (AFAR) Postdoctoral Fellowship for Translational Research on Aging.

Others on the research team include: Ming Xu, Ph.D.; Tamara Tchkonia, Ph.D.; Husheng Ding, Ph.D.; Ellen Lubbers; Tamar Pirtskhalava, Ph.D.; Thomas White, Ph.D.; Kurt Johnson; Michael Stout, Ph.D.; Vojtech Mezera, M.D., Ph.D.; Nino Giorgadze; Michael Jensen, M.D.; Nathan LeBrasseur, Ph.D.; all of Mayo Clinic, as well as Mikolaj Ogrodnik, of Mayo Clinic, Newcastle University Institute for Ageing, Newcastle University, and Institute for Cell and Molecular Biosciences, Newcastle University.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayoclinic
or http://newsnetwork.mayoclinic.org/.

Please login or become a member to post a comment.

multigenerational African American family sitting on couch